ArticleInternational journal of antimicrobial agents2025
Piperacillin/tazobactam clearance predicted by non-creatinine based estimates of GFR in critically ill adults.
Article in International journal of antimicrobial agents, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Impact of mGFR Versus eGFR on the Pharmacokinetics of a Renally Excreted Model Drug in Older Medical Patients: A Proof-of-Concept Trial.Kidney international reports · 2026Article
- Population Pharmacokinetics and Dosing Regimen Optimization of Piperacillin in Critically Ill Patients.Drug design, development and therapy · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
BACKGROUND AND
objectiveAs a renally-eliminated beta-lactam antibiotic, estimated glomerular filtration rate (eGFR) is a central component of piperacillin/tazobactam pharmacokinetics. This study aimed to determine the optimal eGFR equation for inclusion in population pharmacokinetic models for piperacillin and tazobactam among critically ill adults.
methodsThe study included critically ill adults treated with piperacillin/tazobactam at a single academic medical center between 2018 and 2022. Excluded individuals had acute kidney injury, received kidney replacement therapy, or had extracorporeal membrane oxygenation at piperacillin/tazobactam initiation. Non-linear mixed effects population pharmacokinetic models using eGFR equations with creatinine, cystatin C, or both were developed and compared.
resultsUsing 377 samples from 120 critically ill patients, we found that a two-compartment model with first-order elimination best fit the piperacillin data and a one-compartment model with first-order elimination best fit the tazobactam data. For piperacillin, the final population mean parameters (standard error) were 8.36 (0.55) L/h for CL and 12.96 (1.17) L for V1. The values for Q and V2 were fixed at 0.98 L/h and 18 L, respectively, due to low interindividual variation in these parameters. For tazobactam, the final population mean parameters were 8.12 (0.52) L/h for CL and 16.87 (1.44) L for V. Both final models identified eGFR
conclusionsAn eGFR equation that includes cystatin C improves the predictive performance of pharmacokinetic models for piperacillin/tazobactam in critically ill adults.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.